Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy

NF-κB and androgen receptor variant expression correlate with human BPH progression

(2015) David C. Austin et al.   PROSTATE

Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer

(2014) C. Liu et al.   CLINICAL CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression

(2014) R Jin et al.   ONCOGENE

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Melatonin MT1 receptor-induced transcriptional up-regulation of p27Kip1 in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and

(2012) Stephen Y. W. Shiu et al.   JOURNAL OF PINEAL RESEARCH

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Melatonin as Adjuvant Cancer Care With and Without Chemotherapy

(2011) Dugald Seely et al.   INTEGRATIVE CANCER THERAPIES

Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer

(2011) Chun W. Tam et al.   JOURNAL OF PINEAL RESEARCH

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

(2011) Rong Hu et al.   PROSTATE

NF-κB signaling in prostate cancer: A promising therapeutic target?

(2011) Garima Jain et al.   WORLD JOURNAL OF UROLOGY

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Gαs and Gαq proteins

(2010) Stephen Y. W. Shiu et al.   JOURNAL OF PINEAL RESEARCH

Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?

(2009) Gerhardt Attard et al.   CANCER CELL

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

(2009) Yu Chen et al.   LANCET ONCOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Targeting the androgen receptor pathway in prostate cancer

(2008) Yu Chen et al.   CURRENT OPINION IN PHARMACOLOGY